• Something wrong with this record ?

Fucosyl glycosides for DC-SIGN targeting: Fucosylation strategies, synthesis and binding studies of model compounds

R. Chavan, J. Lefèbre, K. Jochová, H. Dvořáková, C. Rademacher, P. Ménová

. 2025 ; 123 (-) : 118164. [pub] 20250320

Language English Country England, Great Britain

Document type Journal Article

DC-SIGN, a C-type lectin receptor expressed on immune cells, is considered a promising target for immunomodulatory and antiviral therapies. While mannose-based glycomimetics have been extensively studied as DC-SIGN ligands, fucose-based strategies remain underexplored. This study explores the fucosylation of linear alcohols and sugars using eight different fucosyl donors, aiming at designing strategies for the development of fucose-based glycomimetics targeting DC-SIGN. Four types of leaving groups and two different acyl-based protecting groups on the donors were tested. The glycosylation of 3-azidopropan-1-ol exclusively yielded the β-anomer, demonstrating high stereoselectivity. The azido group in the product is versatile, allowing for direct click chemistry reactions or reduction to an amine for further functionalization. Both types of reactions were demonstrated in a model reaction. In the glycosylation of a sugar, a disaccharide moiety of Lewis X antigen was selected as a target molecule. Only one of the eight tested fucosyl donors worked well in this reaction and provided the product in a reasonable yield. The disaccharide was also equipped with the 3-azidopropyl linker, facilitating future modifications. Finally, NMR studies confirmed compatibility of the linker with canonical Ca2+-dependent carbohydrate binding to DC-SIGN, suggesting potential for further development of fucose-based glycomimetics targeting this C-type lectin receptor.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015515
003      
CZ-PrNML
005      
20250731091034.0
007      
ta
008      
250708e20250320enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bmc.2025.118164 $2 doi
035    __
$a (PubMed)40147363
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Chavan, Rohit $u University of Chemistry and Technology, Prague, Technická 5, 16628 Prague 6, Czech Republic
245    10
$a Fucosyl glycosides for DC-SIGN targeting: Fucosylation strategies, synthesis and binding studies of model compounds / $c R. Chavan, J. Lefèbre, K. Jochová, H. Dvořáková, C. Rademacher, P. Ménová
520    9_
$a DC-SIGN, a C-type lectin receptor expressed on immune cells, is considered a promising target for immunomodulatory and antiviral therapies. While mannose-based glycomimetics have been extensively studied as DC-SIGN ligands, fucose-based strategies remain underexplored. This study explores the fucosylation of linear alcohols and sugars using eight different fucosyl donors, aiming at designing strategies for the development of fucose-based glycomimetics targeting DC-SIGN. Four types of leaving groups and two different acyl-based protecting groups on the donors were tested. The glycosylation of 3-azidopropan-1-ol exclusively yielded the β-anomer, demonstrating high stereoselectivity. The azido group in the product is versatile, allowing for direct click chemistry reactions or reduction to an amine for further functionalization. Both types of reactions were demonstrated in a model reaction. In the glycosylation of a sugar, a disaccharide moiety of Lewis X antigen was selected as a target molecule. Only one of the eight tested fucosyl donors worked well in this reaction and provided the product in a reasonable yield. The disaccharide was also equipped with the 3-azidopropyl linker, facilitating future modifications. Finally, NMR studies confirmed compatibility of the linker with canonical Ca2+-dependent carbohydrate binding to DC-SIGN, suggesting potential for further development of fucose-based glycomimetics targeting this C-type lectin receptor.
650    12
$a lektiny typu C $x metabolismus $x antagonisté a inhibitory $7 D037181
650    12
$a molekuly buněčné adheze $x metabolismus $x antagonisté a inhibitory $7 D015815
650    12
$a receptory buněčného povrchu $x metabolismus $x antagonisté a inhibitory $7 D011956
650    12
$a fukosa $x chemie $7 D005643
650    12
$a glykosidy $x chemie $x chemická syntéza $x farmakologie $x metabolismus $7 D006027
650    _2
$a lidé $7 D006801
650    _2
$a glykosylace $7 D006031
650    _2
$a molekulární struktura $7 D015394
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lefèbre, Jonathan $u Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria; Department of Microbiology, Immunobiology and Genetics, Max F. Perutz Laboratories, University of Vienna, Biocenter 5, 1030 Vienna, Austria; Vienna Doctoral School of Pharmaceutical, Nutritional and Sport Sciences, University of Vienna, Vienna, Austria
700    1_
$a Jochová, Kateřina $u University of Chemistry and Technology, Prague, Technická 5, 16628 Prague 6, Czech Republic
700    1_
$a Dvořáková, Hana $u University of Chemistry and Technology, Prague, Technická 5, 16628 Prague 6, Czech Republic
700    1_
$a Rademacher, Christoph $u Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria; Department of Microbiology, Immunobiology and Genetics, Max F. Perutz Laboratories, University of Vienna, Biocenter 5, 1030 Vienna, Austria. Electronic address: christoph.rademacher@univie.ac.at
700    1_
$a Ménová, Petra $u University of Chemistry and Technology, Prague, Technická 5, 16628 Prague 6, Czech Republic. Electronic address: petra.menova@vscht.cz
773    0_
$w MED00000769 $t Bioorganic & medicinal chemistry $x 1464-3391 $g Roč. 123 (20250320), s. 118164
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40147363 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091029 $b ABA008
999    __
$a ok $b bmc $g 2366388 $s 1252640
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 123 $c - $d 118164 $e 20250320 $i 1464-3391 $m Bioorganic & medicinal chemistry $n Bioorg Med Chem $x MED00000769
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...